Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of FOLFOX plus cetuximab with concurrent radiotherapy in stage III esophageal cancer
2006-005550-72Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab and oxaliplatin in esophageal cancer, esophageal adenocarcinoma (EAC) and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Objective response rate. Started Apr 2007; status: completed.
02
Drugs
cetuximaboxaliplatin
03
Conditions
esophageal canceresophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2006-005550-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005550-72.